A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms Clinical Trial

Official title: A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Rifampin On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib

Status Completed

Clinical Trial Summary

This open-label, multi-center, three-period, one sequence study will investigate the effect of rifampin on the pharmacokinetics of vemurafenib in patients with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant tumor type that harbors a V600-activating mutation of BRAF without acceptable standard treatment options. Patients will receive a single dose of vemurafenib in Periods A and C and multiple doses of rifampin in Periods B and C. Eligible patients will have the option to continue treatment with vemurafenib as part of an extension study (NCT01739764). The anticipated time on study treatment is approximately 24 days.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malignant Melanoma, Neoplasms
• Melanoma

• NCT number: NCT01765543
• Study type: Interventional
• Source: Hoffmann-La Roche
• Status: Completed
• Phase: Phase 1
• Start date: July 2013
• Completion date: January 2016